Respuesta a vismodegib en un meduloblastoma recurrente.

Laura Bernal; Nicolás Useche; Sonia Bermúdez; Andrés Felipe Cardona

doi:10.51643/22562915.353

Respuesta a vismodegib en un meduloblastoma recurrente.

Response to vismodegib in recurrent meduloblastoma.

Published 2013-10-01

Open | Download

PDF (Spanish) FLIP

Issue

Vol. 2 No. 3 (2013): Octubre

Section

Images in hematology and oncology

How to Cite

Respuesta a vismodegib en un meduloblastoma recurrente.

Rev. colomb. hematol. oncol. [Internet]. 2013 Oct. 1 [cited 2024 Dec. 22];2(3):45-51. Disponible en: https://doi.org/10.51643/22562915.353

DOI

https://doi.org/10.51643/22562915.353

Dimensions

PlumX

license

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Laura Bernal

Fundación Santa Fe de Bogotá

Nicolás Useche

Fundación Santa Fe de Bogotá

Sonia Bermúdez

Fundación Santa Fe de Bogotá

Andrés Felipe Cardona

Fundación Santa Fe de Bogotá ; Fundación para la Investigación Clínica y Molecular Aplicada del Cáncer (FICMAC)

Show authors biography

Laura Bernal,

Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

Nicolás Useche,

Diagnostic Image Department, Neuro-Radiology Section, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

Sonia Bermúdez,

Diagnostic Image Department, Neuro-Radiology Section, Fundación Santa Fe de Bogotá (Bogotá, Colombia).

Andrés Felipe Cardona,

Clinical and Translational Oncology Group, Institute of Oncology, Fundación Santa Fe de Bogotá (Bogotá, Colombia). Foundation for Clinical and Applied Cancer Research (FICMAC); ONCOLGroup associate researcher.

.

Article visits 174 | PDF visits 117

Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14 Suppl 5:v1-49.
Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173-8.
Shonka N, Brandes A, De Groot JF. Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. Oncology (Williston Park). 2012;26(11):1083-91.
Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199(2):193-7.
Watson S, Serrate C, Vignot S. Voie de signalisation Sonic Hedgehog : du développement embryonnaire aux thérapies moléculaires ciblées. Bulletin du Cancer. 2010;97(12):1477-83.
Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: progress to date. Drugs. 2013;73(7):613-23.
Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002;16(21):2743-8.
LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502-11.
Gajjar AJ, Amar J. A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B). J Clin Oncol. 2013; suppl: abstr 2035.
Weiss GJ, Korn RL. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors. Cancer. 2012;118(21):5310-9.